Potential role of the membrane in hERG channel functioning and drug-induced long QT syndrome

Biochimica et Biophysica Acta - Biomembranes

Volumn 1798, Issue 9, 2010, Pages 1651-1662

  Chartrand, Étienne ^a   Arnold, Alexandre A ^a   Gravel, Andrêe ^a   Jenna, Sarah ^a   Marcotte, Isabelle ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Bicelles; Cardiotoxic drugs; Drugprotein interaction; Membrane protein interaction; NMR spectroscopy; Voltage gated potassium channel

Indexed keywords

BEPRIDIL; CETIRIZINE; DIPHENHYDRAMINE; IODINE; IODINE 583; PENTAMIDINE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 597; ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; DRUG BINDING SITE; DRUG INDUCED DISEASE; DRUG STRUCTURE; HEART MUSCLE FIBER MEMBRANE POTENTIAL; LIQUID; LONG QT SYNDROME; MEMBRANE BINDING; MEMBRANE STABILIZATION; MICELLE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; SOLID STATE; AMINO ACID SEQUENCE; CELL MEMBRANE; CHEMICALLY INDUCED; CHEMISTRY; HUMAN; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; CELL MEMBRANE; CIRCULAR DICHROISM; HUMANS; LONG QT SYNDROME; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; TRANS-ACTIVATORS;

EID: 77954657807     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2010.05.019     Document Type: Article

References (93)

1. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA 2000, 97:12329-12333.
2. Jiang Y., Lee A., Chen J., Cadene M., Chait B.T., MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417:515-522.
3. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
4. Recanatini M., Poluzzi E., Masetti M., Cavalli A., De Ponti F. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 2005, 25:133-166.
5. MacKinnon R. Pore loops: an emerging theme in ion channel structure. Neuron 1995, 14:889-892.
6. Roden D.M., Temple R. The US Food and Drug Administration cardiorenal advisory panel and the drug approval process. Circulation 2005, 111:1697-1702.
7. Shah R.R. Drug-induced QT interval prolongation - regulatory guidance and perspectives on hERG channel studies. The hERG cardiac potassium channel: structure, function and long QT syndrome 2005, 251-285. John Wiley & Sons Ltd, Chichester. D.J. Chadwick, J. Goode (Eds.).
8. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
9. Brown A.M., Rampe D. Drug-induced long QT syndrome: is HERG the root of all evil. Pharmaceutical News 2000, 7:15-20.
10. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002, 25:263-286.
11. Abriel H., Schlpfer J., Keller D.I., Gavillet B., Biollaz J., Stoller R., Kappenberger L. Molecular and clinical determinants of drug-induced long QT syndrome an iatrogenic channelopathy. Swiss Med. Wkly 2004, 134:685-694.
12. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 2004, 9:276-285.
13. Aronov A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 2005, 10:149-155.
14. + channels. Circ. Res. 1998, 82:386-395.
15. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 2000, 57:367-374.
16. Kamiya K., Mitcheson J.S., Yasui K., Kodama I., Sanguinetti M.C. Open channel block of HERG K(+) channels by vesnarinone. Mol. Pharmacol. 2001, 60:244-253.
17. Sanchez-Chapula J.A., Ferrer T., Navarro-Polanco R.A., Sanguinetti M.C. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 2003, 63:1051-1058.
18. + channel block. J. Biol. Chem. 2002, 277:23587-23595.
19. Sanguinetti M.C., Chen J., Fernandez D., Kamiya K., Mitcheson J., Sanchez-Chapula J.A. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs, in: The hERG cardiac potassium channel: structure, function and long QT syndrome 2005, vol. 266. John Wiley & Sons Ltd, Chichester, pp. 159170.
20. + channels isolated from Centruroides noxius scorpion venom. FASEB J. 1999, 13:953-962.
21. Korolkova Y.V., Kozlov S.A., Lipkin A.V., Pluzhnikov K.A., Hadley J.K., Filippov A.K., Brown D.A., Angelo K., Strobaek D., Jespersen T., Olesen S.P., Jensen B.S., Grishin E.V. An ERG channel inhibitor from the scorpion Buthus eupeus. J. Biol. Chem. 2001, 276:9868-9876.
22. Pardo-Lopez L., Zhang M., Liu J., Jiang M., Possani L.D., Tseng G.-N. Mapping the binding site of a human ether-a-gogo-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule. J. Biol. Chem. 2002, 277:16403-16411.
23. Jiang M., Zhang M., Maslennikov I.V., Liu J., Wu D.-M., Korolkova Y.V., Arseniev A.S., Grishin E.V., Tseng G.-N. Dynamic conformational changes of extracellular S5-P linkers in the hERG channel. J. Physiol. 2005, 569:75-89.
24. Liu J., Jiang M., Tseng G.-N. Structural and functional role of the extracellular S5-P linker in the HERG potassium channel. J. Gen. Physiol. 2002, 120:723-737.
25. Zhang M., Liu J., Tseng G.-N. Gating charges in the activation and inactivation processes of the hERG channel. J. Gen. Physiol. 2004, 124:703-718.
26. + channel S5P extracellular linker. J. Biol. Chem. 2003, 278:42136-42148.
27. Sanders C.R., Schwonek J.P. Characterization of magnetically orientable bilayers in mixtures of dihexanoylphosphatidylcholine and dimyristoylphosphatidylcholine by solid-state NMR. Biochemistry 1992, 31:8898-8905.
28. Marcotte I., Auger M. Bicelles as model membranes for solid- and solution-state NMR studies of membrane peptides and proteins. Concepts Magn. Res. 2005, 24A:17-37.
29. Triba M.N., Warschawski D.E., Devaux P.F. Reinvestigation by phosphorus NMR of lipid distribution in bicelles. Biophys. J. 2005, 88:1887-1901.
30. Coumel P. Safety of bepridil: from review of the European data. Am. J. Cardiol. 1992, 69:75D-78D.
31. Gill A., Flaim S.F., Damiano B.P., Sit S.P., Brannan M.D. Pharmacology of bepridil. Am. J. Cardiol. 1992, 69:11D-16D.
32. + channels IKr and IKs. Therapie 2000, 55:195-202.
33. Choe H., Nah K.H., Lee S.N., Lee H.S., Lee H.S., Jo S.H., Leem C.H., Jang Y.J. A novel hypothesis for the binding mode of HERG channel blockers. Biochim. Biophys. Res. Commun. 2006, 344:72-78.
34. Gilbert J.D., Cahill S.A., McCartney D.G., Lukas A., Gross G.J. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists. Can. J. Physiol. Pharmacol. 2000, 78:407-414.
35. Zareba W., Moss A.J., Rosero S.Z., Hajj-Ali R., Konecki J., Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am. J. Cardiol. 1997, 80:1168-1173.
36. Wharton J.M., Demopulos P.A., Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am. J. Med. 1987, 83:571-576.
37. Pujol M., Carratala J., Mauri J., Viladrich P.F. Ventricular tachycardia due to pentamidine isethionate. Am. J. Med. 1988, 84:980.
38. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., Brown A.M., Kang J., Chen X.-L., Sawamura K., Reynolds W., Rampe D. Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 2005, 312:316-323.
39. Marsh D. CRC Handbook of lipid bilayers 1990, CRC Press Inc., Boca Raton.
40. Schwarz D., Junge F., Durst F., Frolich N., Schneider B., Reckel S., Sobhanifar S., Dotsch V., Bernhard F. Preparative scale expression of membrane proteins in Escherichia coli-based continuous exchange cell-free systems. Nat. Protoc. 2007, 2:2945-2957.
41. Vold R.R., Prosser R.S. Magnetically oriented phospholipid bilayered micelles for structural studies of polypeptides. Does the ideal bicelle exist?. J. Magn. Reson. 1996, 113:267-271.
42. Altieri A.S., Hinton D.P., Byrd R.A. Association of biomolecular systems via pulsed field gradient NMR self diffusion measurements. J. Am. Chem. Soc. 1995, 117:7566-7567.
43. 1H NMR PFG measurements. Phys. Chem. Chem. Phys. 2000, 2:4740-4742.
44. Mayer M., Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 1999, 38:1784-1788.
45. Mayer M., Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 2001, 123:6108-6117.
46. Wang J., Schnell J.R., Chou J.J. Amantadine partition and localization in phospholipid membrane: a solution NMR study. Biochim. Biophys. Res. Commun. 2004, 324:212-217.
47. Bax A., Davis D.G. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 1985, 65:355-360.
48. Jeener J., Meier B.M., Bachmann P., Ernst R.R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 1979, 71:4546-4553.
49. Macura S., Ernst R.R. Elucidation of cross relaxation in liquids by two-dimensional NMR spectroscopy. Mol. Phys. 1980, 41:95-117.
50. Rance M., Byrd R.A. Obtaining high-fidelity spin-1/2 powder spectra in anisotropic media: phase-cycled Hahn echo spectroscopy. J. Magn. Reson. 1983, 52:221-240.
51. Davis J.H., Jeffrey K.R., Bloom M., Valic M.I., Higgs T.P. Quadrupolar echo deuteron magnetic resonance spectroscopy in ordered hydrocarbon chains. Chem. Phys. Lett. 1976, 42:390-394.
52. van Beek J.D. matNMR: A flexible toolbox for processing, analyzing and visualizing magnetic resonance data in Matlab®. J. Magn. Reson. 2007, 187:19-26.
53. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6:277-293.
54. Johnson B.A., Blevins R.A. NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR 1994, 4:603-614.
55. Whitmore L., Wallace B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 2004, 32:W668-W673.
56. Gao X., Wong T.C. Studies of the binding and structure of adrenocorticotropin peptides in membrane mimics by NMR spectroscopy and pulsed-field gradient diffusion. Biophys. J. 1998, 74:1871-1888.
57. 1H NMR investigation of the conformation of methionine-enkephalin in fast-tumbling bicelles. Biophys. J. 2004, 86:1587-1600.
58. Whitehead T.L., Jones L.M., Hicks R.P. Effects of the incorporation of CHAPS into SDS micelles on neuropeptide-micelle binding: separation of the role of electrostatic interactions from hydrophobic interactions. Biopolymers 2001, 58:593-605.
59. Stilbs P. Fourier transform pulsed-gradient spin-echo studies of molecular diffusion. Prog. Nucl. Magn. Reson. Spectrosc. 1987, 19:1-45.
60. Gaemers S., Bax A. Morphology of three lyotropic liquid crystalline biological NMR media studied by translational diffusion anisotropy. J. Am. Chem. Soc. 2001, 123:12343-12352.
61. Luchette P.A., Vetman T.N., Prosser R.S., Hancock R.E.W., Nieh M.-P., Glinka C.J., Krueger S., Katsaras J. Morphology of fast-tumbling bicelles: a small angle neutron scattering and NMR study. Biochim. Biophys. Acta 2001, 1513:83-94.
62. Johannesson H., Halle B. Solvent diffusion in ordered macrofluids: A stochastic simulation study of the obstruction effect. J. Chem. Phys. 1996, 104:6807-6817.
63. Andersson A., Mäler L. Size and shape of fast-tumbling bicelles as determined by translational diffusion. Langmuir 2006, 22:2447-2449.
64. Chen A., Shapiro M. Nuclear Overhauser effect on diffusion measurements. J. Am. Chem. Soc. 1999, 121:5338-5339.
65. Lucas L.H., Yan J., Larive C.K., Zartler E.R., Shapiro M.J. Transferred nuclear overhauser effect in nuclear magnetic resonance diffusion measurements of ligand-protein binding. Anal. Chem. 2003, 75:627-634.
66. 31P nuclear magnetic resonance and the head group structure of phospholipids in membranes. Biochim. Biophys. Acta 1978, 515:105-140.
67. Seelig J. Deuterium magnetic resonance: theory and application to lipid membranes. Q. Rev. Biophys. 1977, 10:353-418.
68. 2H-NMR. Biochim. Biophys. Acta 1983, 737:117-171.
69. 31P NMR first spectral moment study of the partial magnetic orientation of phospholipid membranes. Biophys. J. 1999, 77:888-902.
70. Sternin E., Nizza D., Gawrish K. Temperature dependence of DMPC/DHPC mixing in a bicellar solution and its structural implications. Langmuir 2001, 17:2610-2616.
71. Nieh M.P., Glinka C.J., Krueger S., Prosser R.S., Katsaras J. SANS study on the effect of lanthanide ions and charged lipids on the morphology of phospholipid mixtures. Small-angle neutron scattering. Biophys. J. 2002, 82:2487-2498.
72. Arnold A., Labrot T., Oda R., Dufourc E.J. Cation modulation of bicelle size and magnetic alignment as revealed by solid state NMR and electron microscopy. Biophys. J. 2002, 82:2667-2680.
73. Lind J., Graslund A., Maler L. Membrane interactions of dynorphins. Biochemistry 2006, 45:15931-15940.
74. Sanders C.R., Sönnichsen F. Solution NMR of membrane proteins: practice and challenges. Magn. Reson. Chem. 2006, 44:S24-S40.
75. Abi-Char J., Maguy A., Coulombe A., Balse E., Ratajczak P., Samuel J.-L., Nattel S., Hatem S.N. Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J. Physiol. 2007, 582:1205-1217.
76. Boland L.M. Drzweiecki, Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem. Biophys. 2008, 52:59-84.
77. Wishart D.S., Sykes B.D., Richards F.M. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 1992, 31:1647-1651.
78. Bazzoni G., Rasia M. Effects of amphipathic drug on the rheological properties of the cell membrane. Blood Cells 1998, 24:552-559.
79. 2H solid-state NMR. Biophys. J. 2003, 85:328-339.
80. Wang J., Trudeau M.C., Zappia A.M., Robertson G.A. Regulation of deactivation by an amino terminal domain in human ether-à-go-go-related gene potassium channels. J. Gen. Physiol. 1998, 112:637-647.
81. +channels. J. Gen. Physiol. 2000, 115:749-758.
82. Roti Roti E.C., Myers C.D., Ayers R.A., Boatman D.E., Delfosse S.A., Chan E.K.L., Ackerman M.J., January C.T., Robertson G.A. Interaction with GM130 during HERG ion channel trafficking. J. Biol. Chem. 2002, 277:47779-47785.
83. Tseng G.-N., Sonawane K.D., Korolkova Y.V., Zhang M., Liu J., Grishin E.V., Guy H.R. Probing the outer mouth structure of the hERG chanel with peptide toxin footprinting and molecular modeling. Biophys. J. 2007, 92:3524-3540.
84. + channel. J. Biol. Chem. 2009, 284:1000-1008.
85. Lundbaek J.A., Birn P., Girshman J., Hansen A.J., Andersen O.S. Membrane stiffness and channel function. Biochemistry 1996, 35:3825-3830.
86. Lee A.G. Lipid-protein interactions in biological membranes: a structural perspective. Biochim. Biophys. Acta 2003, 1612:1-40.
87. van Meer G., Voelker D.R., Feigenson G.W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008, 9:112-124.
88. Krueger-Koplin R.D., Sorgen P.L., KrÜeger-Koplin S.T., Rivera-Torres I.O., Cahill S.M., Hicks D.B., Grinius L., Krulwich T.A., Girvin M.E. An evaluation of detergents for NMR structural studies of membrane proteins. J. Biomol. NMR 2004, 17:43-57.
89. Perozo E., Kloda A., Cortes D.M., Martinac B. Physical principles underlying the transduction of the bilayer deformation forces during mechanosensitive channel gating. Nat. Struct. Biol. 2002, 9:696-703.
90. Mouritsen O.G., Jorgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm. Res. 1998, 15:1507-1519.
91. + channel gating and voltage sensor toxin sensitivity depend on the mechanical state of the lipid membrane. Proc. Natl Acad. Sci. USA 2008, 105:19276-19281.
92. Baenziger J.E., Ryan S.E., Goodried M.M. V. N.Q., R.M. Sturgeon, C.J.B. daCosta, Lipid composition alters drug action at the nicotinic acetylcholine receptor. Mol. Pharmacol. 2008, 73:880-890.
93. Sargent D.F., Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl Acad. Sci. USA 1986, 83:5774-5778.